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Summary 
Background: Laboratory thyroid function tests play a cen-
tral role in the diagnosis of thyroid disorders. The aim of
our cross-sectional study was to determine reference values
for thyroid tests in a rigorously selected group of
Montenegrin females, investigate the impact of possible
age-related changes and the influence of the interassay
bias between three frequently used immunoassays. 
Methods: Female subjects were randomly selected, aged
between 20 and 69 and 946 of them met the selection cri-
teria. TSH, fT3, fT4, thyroid peroxidase and thyroglobulin
antibodies were measured. Eighty samples were further
analyzed on two other immunochemistry platforms.
Results: Median TSH progressively increased with age,
there was no difference in fT3, while fT4 was significantly
higher in the two oldest groups compared to the others.
When using the age-related 97.5 percentile of TSH the
percentage of reclassification was highest in the 20–29
years of age group (5.2%, p<0.05). In the oldest band,
7.7% had TSH values above cohort-specific and below the
age-related upper reference limit. Bland-Altman bias plots
revealed the highest interassay absolute mean difference
between compared TSH assays of 24.5% and for fT4
assays of 13.8%. 
Conclusions: The correlation coefficients between fT3
assays from different manufacturers were low. Serum TSH
and fT4 concentrations increased with age and the imple-
mentation of age-specific TSH reference intervals would be
of interest. The bias between the three commercial
Kratak sadr`aj
Uvod: Laboratorijski testovi za procjenu funkcije {titne `lije-
zde imaju centralno mjesto u dijagnostici poreme}aja
njene funkcije. Cilj na{eg istra`ivanja bio je odrediti refe-
rentne vrijednosti za ove testove u rigorozno odabranoj
grupi crnogorskih `ena, istra`iti uticaj starosne dobi, kao i
interesej razlike izme|u tri ~esto kori{}ene imunohemijske
platforme, na dobijene vrijednosti. 
Metode: 946 ispitanica, slu~ajno odabranih u uzrastu iz -
me|u 20 i 69 godina, ispunile su kritriju me za izbor u refe-
rentnu populaciju. Mjereni su: TSH, fT3, fT4, tireoperoksida-
zna i tireoglobulinska antitijela. Osam deset uzoraka dodatno
je analizirano na dvije razli~ite imunohemijske platforme. 
Rezultati: Medijana TSH progresivno je rasla sa godinama,
nije bilo razlike u vrijednostima fT3, dok je fT4 bio znatno
ve}i u dvije najstarije grupe u pore|enju sa ostalim. Pri -
mjena 97,5 percentila vrijednosti TSH, karakteristi~nog za
razli~ite starosne grupe, uzrokovala je reklasifikaciju rezul-
tata iz normalnih u patolo{ke u svim grupama (najve}i pro-
cenata u 20–29 godina grupi, 5,2%, p <0,05), izuzev
najstarije. U najstarijoj grupi 7,7% ispitanica imalo je vrijed-
nosti TSH iznad populacione, a u granicama za tu grupu
dobijenih referentnih vrijednosti. Koncentracije serumskog
TSH i fT4 rasle su sa godinama, te bi primjena referentnih
vrijednosti specifi~nih za datu starosnu grupu bila od zna -
~aja. Najve}a apsolutna razlika srednjih vrijednosti izme|u
TSH testova bila je 24,5%, a izme|u fT4 testova 13,8%.
Zaklju~ak: Koeficijenti korelacije izme|u fT3 testova ra zli -
~itih proizvo |a~a bili su niski. Odstupanje izme|u tri ~esto
List of abbreviations: SCH, subclinical hypothyroidism; TFT,
thyroid function tests
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Introduction
The signs and symptoms of thyroid diseases,
especially subclinical hypothyroidism (SCH), are nei-
ther sensitive nor specific, so diagnosis mainly
depends on a laboratory thyroid function tests (TFT).
Therefore, the distinction between a normal and an
abnormal TFT result is critical in the recognition of
thyroid disorders. The prevalence of thyroid dysfunc-
tion is 5–10 times higher in women compared to
men, which might be explained by range of factors
(1). In the female population, thyroid hormones play
an important role in normal ovarian function (2), so
reference limits for women in their reproductive peri-
od could be of help, especially in fertility challenged
ones. (3) The measurement of the thyroid-stimulating
hormone (TSH) is the most sensitive and widely used
as a »first-step« screening test for primary thyroid dis-
orders (4). The determination of its reference limits
(especially the upper limit) is challenging for many
different reasons and has been a subject of ongoing
debate for the last fifteen years. Median population
thyrotropin values are usually between 1–1.5 mU/L
(5, 6) but they do not have a normal distribution, and
rather display a right skewed one, with a long tail
towards higher values. In 2005, Wartofsky and Dickey
(7) advocated the lowering of the upper TSH limit
from 4–5 mU/L to 2.5 mU/L since more than 95%
of the normal population has a value below this limit.
They suggested that persons with higher values are at
risk of early thyroid failure. In contrast, some authors
point out the huge medical and economical effect of
the proposed change, leading to a nearly 4-fold
increase in the prevalence of hypothyroidism (8, 9)
and the adverse health effects of thyroxin treatment
(10, 11). 
The difficulties in the upper TSH limit determi-
nation are partly caused by differences in the TSH ref-
erence values established in some of the studies con-
ducted so far (12–15). These discrepancies can be
partially explained by different preanalytical and ana-
lytical factors. Preanalytical influences are related to
subject selection criteria, the age of the participants
(16) and the time period of the sample collection
(17). The iodine status of the population is another
possible factor affecting TFT reference values, espe-
cially thyrotropin ones (18) and it changes with age-
ing. The Balkan region has been an iodine deficient
area, but in our country the process of salt iodization
started in the 1950s, so that deficiency was eradicat-
ed and according to the results of the most recent
study conducted in 2007 – intake was adequate (19).
According to some data, in circumstances of iodine
sufficiency, general population TSH values tend to be
higher (14, 20) and increase with age (14, 20, 21) in
contrast to iodine deficient areas (5, 22–24). So, if
population specific reference values are not used, this
could lead to the incorrect classification of elderly
patients regarding thyroid function, in terms of sub-
clinical hypothyroidism in particular. The exact mech-
anisms of the TSH change with ageing have not yet
been clarified.
The analytical factors contributing to the dif -
ferences in reference values are related to the lack
of standardization, differences in the matrix of the
calibrators and the specificity of the antibodies in
the assays used for the determination of TFT
(http://www.acb.org.uk docs/tftguidelinefinal – last
accessed 8 January 2018)). As a consequence, the
bias between assays from different manufacturers is
very noticeable but the Clinical Society’s guidelines
still do not take it into account.
The focus of our research was to determine
accurate TSH, free thyroxin (fT4) and free triiodothy-
ronine (fT3) reference values in the female popula-
tion between the ages of 20 and 69 by implementing
strict reference population selection criteria. Since
some data suggest a change in thyrotropin levels with
ageing, we aimed to determine the age-related
change in this population in order to investigate its
relevance and impact on the laboratory diagnosis of
subclinical hypothyroidism, in terms of both under-
diagnosis and over-diagnosis in different age groups.
In addition, by evaluating the changes in TFT against
age we aimed to contribute to research in to the pos-
sible mechanisms causing this alteration. In order to
determine the impact of method related variability on
TFT values, we compared results of three different,
commonly used assays.
Materials and Methods
Subjects
The study population was randomly selected
and evaluated among female subjects, aged between
20 and 69, who attended a clinical laboratory over
two consecutive years to perform routine laboratory
tests, as a part of their health checkup. All the sub-
jects who voluntarily agreed to participate were self-
reported as healthy and completed a questionnaire
that included the participant’s name, date of birth,
medical history, their personal and family history of
immunoassays indicated that the standardization of thyroid
function tests is a task of great importance.
Keywords: age, assays, reference values, thyroid func-
tion tests
kori{}ena ko mercijalna imunohemijska odre|ivanja ukazu-
je na va`nost stan dardizacije testova za procjenu funkcije
tire oidne `lijezde. 
Klju~ne re~i: godine, odre|ivanja, referentne vrijednosti,
tireoidni funkcionalni testovi
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thyroid diseases and any current medications. The
Ethics Committee of the Clinical Centre of Monte -
negro approved the study and all the subjects gave
written informed consent.
According to the National Academy of Clinical
Biochemistry (NACB) Guidelines for the Diagnosis
and Monitoring of Thyroid Diseases (25) and similar
recommendations issued by the Association of
Clinical Biochemistry and Laboratory Medicine (ACB)
and the British Thyroid Association (BTA) (http://
www.acb.org.uk docs/tftguidelinefinal.pdf (last acces -
sed 8 January 2017)) in 2006 »reference ranges
should be established using specimens collected
between 0800h and 1800h and using 95% confi-
dence limits from log transformed data, the reference
population should have no personal or family history
of thyroid dysfunction, be on no medication known to
alter TSH and have no thyroid antibodies detectable
by a sensitive assay«. The exclusion criteria in our
study were: a personal and/or family history of thyroid
disease, positive thyroglobulin and/or thyroid peroxi-
dase antibodies, taking medicine affecting thyroid
function (oral contraceptives, estrogen, glucocorti-
coids, anti-epileptic drugs, amiodarone, and lithium),
a diagnosis or a suspected case of polycystic ovarian
syndrome (PCOS), a history of severe non-thyroid ill-
ness, pregnancy and breast feeding. Those subjects
with serum values of TSH<0.1 mU/L or TSH>10.0
mU/L were not further analyzed as these results indi-
cate a high probability of thyroid dysfunction (26).
The women included in the study were divided
in to five age-related groups: 20–29, 30–39, 40–49,
50–59 and 60–69 years of age. 
Laboratory measurements
The blood samples were collected between
7:00 – 9:00 AM, after an overnight fast to avoid diur-
nal variation which has been found to have a signifi-
cant and considerable impact on TSH values (15).
After centrifugation at 3000 RPM for 10 minutes, the
serum levels of TSH, fT4, fT3, thyroid peroxidase
anti bodies (TPOAb) and thyroglobulin antibodies
(TgAb) were measured on the same day using an
immuno chemiluminiscent assay on the Architect
i2000 platform (Abbott Laboratories, Diagnostic
Division, Abbott Park, IL, USA). The total (within-la -
boratory) precision for all controls was less than or
equal to 6% for TSH, 7.2% for fT3, 5.5% for fT4,
5.5% for TPOAb and 3.7% for TgAb. The reference
intervals provided by the manufacturer for TSH are
0.35–4.94 mU/L, 9.5-19.0 pmol/L for fT4and 2.5–
5.7 pmol/L for fT3. According to the package, inserts
values of TPOAb lower than 5.6 IU/mL and TgAb
below 4.1mU/L are considered antibody negative. 
Our subset of 80 samples were further analyzed
on a Cobas e411 (Roche Diagnostic, GmbH, Penz -
berg, Germany) and an Immulite 2000XPI (Siemens
Healthcare GmBH, Erlangen, Germany). TSH, fT3
and fT4 were measured, within-run imprecision
determined for all the assays.
Statistical analysis
The Kolmogorov-Smirnov method was used to
test for the normality of the TFT distributions. Since
the TSH, logTSH, fT3 and fT4 values were not nor-
mally distributed in the tested population all the
results of the descriptive statistics are presented by
nonparametric values. The Mann-Whitney test and
Kruskal-Wallis test were used to compare the TFT val-
ues in different subpopulations. The range between
the 2.5th and the 97.5th percentile was used to deter-
mine the reference intervals. Assays from different
manufacturers were compared using the line of best
fit by last square linear regression and Bland-Altman
agreement method. Pearson chi test for categorical
variables was used. A p value < 0.05 was considered
statistically significant. The statistical analyses were
performed using an SPSS version 20.0. 
Results
A total of 946 subjects met the selection criteria
before the measurement of the level of thyroid anti-
bodies. One hundred and fifty-six subjects (16.5%)
with positive TPOAb and/or TgAb were further
excluded from the reference population (Figure 1).
The overall TSH 2.5th and 97.5th percentiles were
0.44 mU/L and 4.13 mU/L. The reference range for
fT3 was 3.3–5.8 pmol/L, and for fT4 it was 10.7–
18.0 pmol/L. The median, inter quartile range and
the 2.5th and 97.5th percentiles of TFT for the five
age-related groups are summarized in Table I.
Median TSH progressively increased with age,
with the first significant increase in the 50–59 years
Reference population (n=790)
Personal / family thyroid disease (n=92)
Drugs affecting thyroiid function (n=37)
PCOS (n=47)
Pregnancy/breast feeding (n=55)
TSH<0.1 mU/L / TSH>10.0 mU/L (n= 2)
TgAb positive (n=48)
TPO Ab positive (n=39)
TgAb and TPOAb positive (n=69)
 
Total number
of surveyed
females
(n=1179)
TFT 
measured
(n=948)
Figure 1 Flow-chart showing selection criteria of female sub-
jects. 
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Figure 2 TSH distribution in the youngest and oldest group.
Table I TSH, fT3 and fT4 concentrations in different age-related groups.
Age group TSH (mU/L) fT3 (pmol/L) fT4 (pmol/L)
(years) N
Median
(IQR*)
2.5th
percentile
97.5th
percentile
Median
(IQR*)
2.5th
percentile
97.5th
percentile
Median
(IQR*)
2.5th
percentile
97.5th
percentile
20–29 172
1.36
(0.99)
0.31 3.21 4.6 (0.9) 3.30 5.80 13.1 (2.0) 10.70 17.53
30–39 198
1.37
(1.21)
0.37 3.60 4.6 (0.9) 3.20 5.70 13.1 (1.6) 10.59 16.11
40–49 157
1.44
(1.24)
0.42 4.20 4.5 (0.9) 3.30 6.30 13.2 (2.1) 10.40 18.10
50–59 133
1.54
(1.10)
0.56 4.43 4.7 (0.8) 3.30 5.80 14.0 (2.32) 10.70 18.14
60–69 130
2.04
(1.34)
0.69 5.07 4.6 (0.7) 3.20 6.50 14.7 (3.0) 11.01 19.08
*- interquartile range 
Table II Age specific distributions of TSH values in the selected population.
Age group (years) Sample Total
Percent in TSH category (mU/L)
<0.4 0.4–2.49 2.5–4.0 >4.0
Total 790 100 1.7 77.2 17.3 3.8
20–29 172 21.8 2.1 85.6 11.3 1.0
30–39 198 25.1 2.0 82.3 13.6 2.1
40–49 157 19.9 1.3 79.8 15.7 3.2
50–59 133 16.8 1.9 75.2 17.6 5.3
60–69 130 16.4 0.8 65.4 27.6 6.2
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of age group. The median TSH value, being 2.04
mU/L, was significantly higher in the oldest group
compared to all the other groups (p<0.01). No sta-
tistically significant differences in the serum values of
free triiodothyronine were observed between any of
the groups (p=0.17). Free thyroxin values were sig-
nificantly higher in the two oldest groups compared to
first, second and third age-related group (p<0.01).
In order to determine the diagnostic relevance
of these population specific and age-related TSH
upper reference limits, the percentages of females
categorized differently compared to the value pro-
posed by manufacturer (4.94 mU/L) were calculated.
When using the age-related 97.5 percentile, the per-
centage of reclassification from normal to abnormal
was highest in the 20–29 years of age group (5.2%,
p<0.05), and in the age band 30–39 it was a still sta-
tistically significant 3.3% (p<0.05), while it was 2.2%
and 2.5% in the groups at 40–49 and 50–59 years of
age. In all these groups the age-specific upper refer-
ence interval was lower compared to that proposed by
the manufacturer. In the oldest band, 1.1% of fe -
males had TSH values above 4.94 mU/L and 7.7%
had TSH values above 4.13 mU/L and below the
age-specific upper reference limit calculated for that
group. 
We analyzed the age-specific distribution of
serum thyrotropin concentrations in the population
(Table II) by categorizing the values in four groups:
lower than 0.40 (Group 1), 0.40–2.49 (Group 2),
2.50–4.00 (Group 3) and greater than 4.00 mU/L
(Group 4). The TSH values progressively shifted
toward higher concentrations with aging. The per-
centage of values in different TSH groups was signif-
icantly different among woman in the five age-related
bands. The frequency of the value categorized in
Group 2 continuously decreased with age, while the
percentage of TSH values in the range 2.50–4.00
mU/L and greater than 4.00 mU/L continuously rose
with age and was highest in the oldest group. The
data suggest that the increase in the median, upper
and lower reference limits, is potentially a conse-
quence of changes in the distribution of TSH with age
(Figure 2). 
In order to evaluate the influence of the different
assays on the TFT reference values, a comparison
Figure 3 Comparison of TSH assays: (A) Regression lines (95% confidence interval) and (B) Bland-Altman plots with mean ±
1.96 SD limits of agreement.
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study analyzing 80 samples using three TSH, fT4 and
fT3 tests produced by different manufacturers was
performed. All the samples were analyzed on the
same day on each platform. For the regression analy-
sis the thyroid hormone results from the Architect
i2000 were used as a reference point and compared
to the other assays (see Figure 3, 4 and 5). The assay
precision for all the tests was determined by analyzing
forty samples in duplicate on each analyzer. For TSH
values of 0.5–5.0 mU/L, the CVs were: 1.6% for the
Architect i2000, 4.1% for the Immulite 2000XP and
2.2 % for the Cobas e411 assay. In terms of the fT4
assay, the CVs for a range of values from 10 pmol/L
to 20 pmol/L: were 2.2% (on the Architect i2000),
2.7% (on the Immulite 2000XP) and 2.1% (on the
Cobas e411). The CVs for the fT3 values of 3.0–6.5
pmol/L were similar (2.5% on the Architect i2000
and 2.7% on the Cobas e411) except for those given
by the Immulite 2000XP, on which the value was
higher (5.9%).
The regression analyses for the TSH values in
the subset of 80 samples revealed the slope of 1.16
from the Cobas e411 and 0.92 from the Immulite
2000XP compared to the Architect i2000 results
(Figure 3A). The Bland-Altman plots representing the
relationship between the difference and the mean of
three TSH assays are shown in Figure 3B. A positive
bias of 12.9% was observed for TSH results measured
with the Architect i2000 compared to Immulite
2000XP which yielded higher results on the first plat-
form. By contrast, bias between Architect i2000/Co -
bas e411 and Immulite 2000XP/Cobas e411 was
negative (-11.6% and -24.5%, respectively). It is
important to note that the manufacturer-proposed
upper reference limits for the Immulite 2000XP and
the Cobas e411 are the same (4.20 mU/L) despite
the difference obtained.
In terms of the fT4 assays, the slope values were
very similar to those for the TSH, 1.15 for the Cobas
Figure 4 Comparison of fT4 assays: (A) Regression lines (95% confidence intervals) and (B) Bland-Altman plots with mean ±1.96
SD limits of agreement.
e411 and 0.92 for the Immulite 2000XP, when com-
pared to the Architect i2000 analyzer (Figure 4A). The
Bland-Altman agreement method for fT4 assays
showed the highest mean difference between Archi tect
i2000 and Immulite 2000XP of 13.8% (Figure 4B).
The correlation coefficients between fT3 con-
centrations in the same samples on different analyz-
ers were low, with Abbott versus Roche giving 0.38
and Abbott versus Siemens producing 0.64, respec-
tively (Figure 5A). Mean differences between three
fT3 assays were -7.8%, 3.8% and 4.1% (Figure 5B). 
Discussion
To the best of our knowledge this is the first
study designed to establish the age-related changes
in the reference intervals of thyroid function tests in
the South European – Balkan region which takes a
population-based approach. 
The overall reference range for TSH at 0.44
mU/L – 4.13 mU/L was similar to one proposed in
the 2012 American Association of Clinical Endo -
crinologists (AACE) and American Thyroid Associ -
ation (ATA) guidelines for a third generation TSH
assay in iodine sufficient areas (0.45 mU/L – 4.12
mU/L) (18). The upper limit was very similar to the
one reported in a study conducted in another part of
the Balkan region (4.20 mU/L) based on the indirect
estimate of reference limits (12), but the values for
different age bands were not in agreement. The cal-
culated upper reference interval in our study was
higher with regard to the data obtained from iodine
deficient areas (14, 15). In two studies performed in
Northern Germany, at an interval of ten years, during
which iodine fortification was introduced, the upper
TSH reference interval shifted towards the right and
the upper limit (with no significant gender differ-
ences) raised from 2.12  mU/L (14) to 3.29 mU/L
(15). Taken together, this results are in accordance
with the recent AACE and ATA guidelines (18) under-
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Figure 5 Comparison of fT3 assays: (A) Regression lines (95% confidence intervals) and (B) Bland-Altman plots with mean ±1.96
SD limits of agreement.
lining the influence of current iodine status on the
thyrotropin range.
Our reference interval for fT4 was narrower
compared to that proposed by the manufacturer and
in agreement with the results of the cross-sectional
study (10.5–18.9 pmol/L) performed using the same
method (12). The calculated fT3 2.5th percentile was
higher and 97.5th percentile similar to those that
were proposed. In a study performed in Spain (27),
using the same method, the lower fT3 reference limit
(2.27–5.18 pmol/L) was more similar to that sug-
gested by the manufacturers, but the age selection
criteria were different and the number of subjects
considerably lower when compared to our study.
Different data suggest that the change in thy-
rotropin levels with age varies depending on the
iodine status of the population. The results of our
investigation are consistent with some other previous-
ly conducted large population studies in areas with
adequate iodine supplementation (6, 22, 24), show-
ing that the median, lower and upper reference limits
of the serum thyrotropin values of female subjects
continuously increased with age. Data from NHANES
III show an increase in the hormone values with age
in subjects with no biochemical or clinical signs of thy-
roid disease (28). The longitudinally designed study
of Bremner et al, with 1212 of participants tested
twice across an interval of thirteen years, has shown
the association between ageing and an increase in
TSH values (being significantly greater in the older
population) without a significant change in fT4 con-
centrations (24). By contrast, some cross-sectional
studies in populations with a mild or moderate iodine
deficiency, in the absence of thyroid disease, have
demonstrated a decrease in thyrotropin concentra-
tions with aging (14, 20, 21). Based on this data, the
iodine supplementation of the investigated popula-
tion was adequate. 
As previously mentioned, in a study performed
in another part of the Balkan region (12) based on
the indirect estimate of TFT reference ranges, the
97.5 percentile of the TSH values in the youngest
subjects (3.82 mU/L) was higher compared to ours
(3.21 mU/L). The probable causes of this are related
to the different approach used in subject selection
and the inclusion of subjects younger than 20 years
old in the Serbian study. In our study the question
related to the subject's medical history included a
sub-question on a diagnosis or suspected case of
PCOS (which usually becomes apparent in the teens
or early 20s) which is associated with a high preva-
lence of thyroid and autoimmune thyroid conditions
(29), so it is possible that the inclusion of a greater
number of patients with this condition affected the
upper thyrotropin reference level in the youngest
group in the Serbian study.
By contrast to a study performed in Western
Australia (30), we had a significantly high percentage
of females in the two youngest groups classified dif-
ferently when the calculated age-specific upper TSH
reference limits were applied. This is probably a con-
sequence of the different thyrotropin values used for
comparison. We evaluated the manufacturer pro-
posed upper limit (4.94 mU/L) while in the investiga-
tion of Kahapola-Arachchige et al the results were
compared with a much lower »common« cut-off of
4.0 mU/L. The differences in subject selection criteria
could further contribute to this discordance.
Although the definition of subclinical hypothy-
roidism (SCH) is still controversial, in the female pop-
ulation of reproductive age (20–40 years old) there is
sufficient data connecting it with fertility (2, 3, 31,
32). Our findings suggesting that the upper TSH ref-
erence level for the general population is slightly too
high and that the use of an age-related upper limit for
this population would be of interest.
In our oldest group, a significant percentage of
patients would have been misclassified as hypothyroid
if the upper TSH limit specific to that age group had
not been applied. The results of various different
studies (5, 23, 33) are consistent with our data, de -
monstrating that higher concentrations of TSH in
older patients are not always an indication of the need
for thyroxin treatment. 
We did not find any age-related change in fT3
values. In a study conducted in southern Italy a reduc-
tion in fT3 in advanced age subjects as a result of
metabolic adjustments to a lower level of oxygen con-
sumption, was found (34), but since our population
was comprised of females who were younger than 70
years of age it is possible that this decline was not yet
noticeable. 
The current data on fT4 changes with age are
conflicting. In our subjects, fT4 increased with age,
with values significantly higher in the two oldest
cohorts compared to the younger groups. The longi-
tudinal study in an iodine sufficient area by Bremner
et al. (24) showed that an increase in TSH was not
followed by a decrease or even a small increase in
FT4 levels with age in the elderly. A Cardiovascular
Health Study in a very elderly subgroup found that a
serum TSH increase by 13% over 13 years of follow-
up was associated with a 1.7% increase in FT4 (35).
In a historically iodine-deficient region in the Nether -
lands, FT4 levels were negatively associated with age
in subjects aged 35–60 and positively associated in
the elderly, aged 60 or older (36).
TSH values distribution analysis showed that the
peak frequencies shifted towards higher concentra-
tions with age (Figure 2). If the increase in the upper
reference limit was a result of an increased preva-
lence of hypothyroidism, they would occur at the
same TSH values in all groups. Therefore, the alter-
ation of values with age, at least to some degree, rep-
resent an age-specific change in thyrotropin towards
J Med Biochem 2019; 38 (1) 29
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higher values, as has been found in some other stud-
ies (6, 22). The absence of a fall in the serum fT4 val-
ues further contributes to the evidences that the age-
related rise in TSH, in populations with adequate
iodine intake, is not a consequence of occult thyroid
diseases, but rather of an alteration in the TSH secre-
tion set point. If the impaired TSH bioactivity or
reduced responsiveness of the thyroid gland to the
hormone with age were causing higher circulating
TSH values, then thyroxine concentration would not
be significantly different. But the type of change in
fT4 values observed in our study suggests that in -
creased TSH secretion could be a result of the
impaired sensitivity of TSH-producing cells to thyroid
hormones by the down-regulation of type 2 iodothy-
ronine deiodinase activity in the pituitary (37). More
studies are needed to clarify the exact causes of this
TSH increase with age.
For every evaluated thyrotropin assay the preci-
sion was acceptable and calibrators traceable to the
WHO Second International Reference Preparation
80/558, but a bias between assays was evident.
Immulite i2000 and Cobas e411 had proportional
biases (with slope values of 1.16 and 0.92, respec-
tively) compared to Architect i2000 TSH values and
the Bland-Altman method showed the mean absolute
difference between three methods of 11.6%, 12.9%
and 24.5%. Those differences suggest that clinical
guidelines should take in to account the bias between
various commercial assays when »cut-off« TSH values
are proposed. The proposed harmonization of thy-
rotropin assays may lead to the better agreement of
results in the future (38). 
The possible standardization of fT4 assays,
according to an international conventional reference
procedure, would change results significantly – per-
haps by as much as 80% at the upper limit of the nor-
mal range – for some assays (39). The three assays
compared in our study did not exhibit such a signifi-
cant difference. Even the extreme absolute difference
between assays described by the 95% limits of agree-
ment did not exceed 36%. The highest fT4 between
method bias of 13.8% could have an impact on the
diagnosis of thyroid dysfunction, particularly if the
TSH values are between the upper limit of a reference
range and 10 mU/L. 
The regression analyses revealed notable inter-
assay variability in fT3 measurements in our study.
Despite smaller mean differences, the Bland-Altman
plots pointed out absolute extreme difference
described by 95% limits of agreement exceeding 59%
between the methods. Since standardization is not
expected in the near future, the recommendation to
measure this hormone with the same assay for follow-
up should probably remain in place. 
Conclusion
In conclusion, in this selected reference female
population, the serum TSH and fT4 concentrations
increased with age due to modifications to the TSH
set-point. The implementation of age-specific TSH
reference intervals would be of interest especially for
the youngest and the oldest cohort. Our results sug-
gest the adequate iodine supplementation of the pop-
ulation. The impact of different TFT assays on report-
ed values is significant (being similar to effects of age,
except for fT3) and the standardization and/or har-
monization of TFT remains a task of great impor-
tance. Until the realization of that goal, all measured
TFT results should be evaluated in relation to popula-
tion and assay specific decision limits.
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